Zobrazeno 1 - 10
of 63
pro vyhledávání: '"Laura Evgin"'
Autor:
Mason J. Webb, Thanich Sangsuwannukul, Jacob van Vloten, Laura Evgin, Benjamin Kendall, Jason Tonne, Jill Thompson, Muriel Metko, Madelyn Moore, Maria P. Chiriboga Yerovi, Michael Olin, Antonella Borgatti, Mark McNiven, Satdarshan P. S. Monga, Mitesh J. Borad, Alan Melcher, Lewis R. Roberts, Richard Vile
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-18 (2024)
Abstract Although patients benefit from immune checkpoint inhibition (ICI) therapy in a broad variety of tumors, resistance may arise from immune suppressive tumor microenvironments (TME), which is particularly true of hepatocellular carcinoma (HCC).
Externí odkaz:
https://doaj.org/article/3cf0fc38fa494b069051f0ff5e7872c6
Autor:
Timothy Kottke, Jason Tonne, Laura Evgin, Christopher B. Driscoll, Jacob van Vloten, Victoria A. Jennings, Amanda L. Huff, Brady Zell, Jill M. Thompson, Phonphimon Wongthida, Jose Pulido, Matthew R. Schuelke, Adel Samson, Peter Selby, Elizabeth Ilett, Mark McNiven, Lewis R. Roberts, Mitesh J. Borad, Hardev Pandha, Kevin Harrington, Alan Melcher, Richard G. Vile
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
Oncolytic viruses, such as vesicular stomatitis virus (VSV), are a promising class of cancer therapeutics. Here the authors report that a mutation in the CSDE1 gene renders cancer cells resistant to VSV replication and oncolysis, but a mutation-deriv
Externí odkaz:
https://doaj.org/article/0057781c39ce43a79a6659f6e847a415
Autor:
Laura Evgin, Amanda L. Huff, Phonphimon Wongthida, Jill Thompson, Tim Kottke, Jason Tonne, Matthew Schuelke, Katayoun Ayasoufi, Christopher B. Driscoll, Kevin G. Shim, Pierce Reynolds, Dileep D. Monie, Aaron J. Johnson, Matt Coffey, Sarah L. Young, Gary Archer, John Sampson, Jose Pulido, Luis Sanchez Perez, Richard Vile
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-15 (2020)
Oncolytic viruses promote an inflammatory response and elicit anti-tumor immunity. Here the authors show, unexpectedly, that the oncolytic virus, VSVIFNβ, induces type I interferon responses that, when combined with chimeric antigen receptor (CAR) T
Externí odkaz:
https://doaj.org/article/5178c922fdee4c4491424f98809482c4
Autor:
Elizabeth C. Eckert, Rebecca A. Nace, Jason M. Tonne, Laura Evgin, Richard G. Vile, Stephen J. Russell
Publikováno v:
Molecular Therapy: Oncolytics, Vol 16, Iss , Pp 63-74 (2020)
Genetically modified vesicular stomatitis virus (VSV) is an attractive agent for cancer treatment due to rapid intratumoral replication and observed clinical responses. Although VSV selectively kills malignant cells and can boost antitumor immunity,
Externí odkaz:
https://doaj.org/article/5bc51a5e074e4c1d8f38884a5ba05a79
Autor:
Christopher B. Driscoll, Matthew R. Schuelke, Timothy Kottke, Jill M. Thompson, Phonphimon Wongthida, Jason M. Tonne, Amanda L. Huff, Amber Miller, Kevin G. Shim, Amy Molan, Cynthia Wetmore, Peter Selby, Adel Samson, Kevin Harrington, Hardev Pandha, Alan Melcher, Jose S. Pulido, Reuben Harris, Laura Evgin, Richard G. Vile
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-14 (2020)
DNA mutations induced by dysregulated APOBEC3 expression are associated with tumour-progression and therapeutic resistance, but also with the generation of neoepitopes. Here, the authors show that APOBEC3 function can be exploited in a vaccine settin
Externí odkaz:
https://doaj.org/article/0b522666697f4ba891fb72be5cba002f
Autor:
Amanda L. Huff, Phonphimon Wongthida, Timothy Kottke, Jill M. Thompson, Christopher B. Driscoll, Matthew Schuelke, Kevin G. Shim, Reuben S. Harris, Amy Molan, Jose S. Pulido, Peter J. Selby, Kevin J. Harrington, Alan Melcher, Laura Evgin, Richard G. Vile
Publikováno v:
Molecular Therapy: Oncolytics, Vol 11, Iss , Pp 1-13 (2018)
Tumor cells frequently evade applied therapies through the accumulation of genomic mutations and rapid evolution. In the case of oncolytic virotherapy, understanding the mechanisms by which cancer cells develop resistance to infection and lysis is cr
Externí odkaz:
https://doaj.org/article/fd3503b7a0a047429514beaab62c3ec2
Autor:
Neil S. Forbes, Robert S. Coffin, Liang Deng, Laura Evgin, Steve Fiering, Matthew Giacalone, Claudia Gravekamp, James L. Gulley, Hal Gunn, Robert M. Hoffman, Balveen Kaur, Ke Liu, Herbert Kim Lyerly, Ariel E. Marciscano, Eddie Moradian, Sheryl Ruppel, Daniel A. Saltzman, Peter J. Tattersall, Steve Thorne, Richard G. Vile, Halle Huihong Zhang, Shibin Zhou, Grant McFadden
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-24 (2018)
Abstract In this White Paper, we discuss the current state of microbial cancer therapy. This paper resulted from a meeting (‘Microbial Based Cancer Therapy’) at the US National Cancer Institute in the summer of 2017. Here, we define ‘Microbial
Externí odkaz:
https://doaj.org/article/59241f901cfc4e0f9a8a64cfde57e873
Autor:
Matthew J. Atherton, Laura Evgin, Brian A. Keller, Mira M. Shenouda, Kyle B. Stephenson, Richard G. Vile, John C. Bell, David H. Evans, Brian D. Lichty
Publikováno v:
Molecular Therapy: Oncolytics, Vol 7, Iss , Pp 12-16 (2017)
The 10th International Conference on Replicating Oncolytic Virus Therapeutics was held in Vancouver, Canada from October 1–4, 2016. The agenda for the meeting comprised lectures from several streams within the field of oncolytic viral therapeutics.
Externí odkaz:
https://doaj.org/article/ee73db01ad6b4d42a2f6f45d3aa5d607
Autor:
Laura Evgin, Richard G. Vile
Publikováno v:
Cancers, Vol 13, Iss 5, p 1106 (2021)
Oncolytic viruses (OVs) and adoptive T cell therapy (ACT) each possess direct tumour cytolytic capabilities, and their combination potentially seems like a match made in heaven to complement the strengths and weakness of each modality. While providin
Externí odkaz:
https://doaj.org/article/764af349ade94721911cc42564e9cf88
Autor:
Laura Evgin, Carolina S Ilkow, Marie-Claude Bourgeois-Daigneault, Christiano Tanese de Souza, Lawton Stubbert, Michael S Huh, Victoria A Jennings, Monique Marguerie, Sergio A Acuna, Brian A Keller, Charles Lefebvre, Theresa Falls, Fabrice Le Boeuf, Rebecca A Auer, John D Lambris, J Andrea McCart, David F Stojdl, John C Bell
Publikováno v:
Molecular Therapy: Oncolytics, Vol 3, Iss C (2016)
The systemic delivery of therapeutic viruses, such as oncolytic viruses or vaccines, is limited by the generation of neutralizing antibodies. While pseudotyping of rhabdoviruses with the lymphocytic choriomeningitis virus glycoprotein has previously
Externí odkaz:
https://doaj.org/article/03318fbb20d24026bc983751bf71f24d